Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03875573
Title Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute
Indications

Her2-receptor negative breast cancer

Therapies

Durvalumab

Durvalumab + Oleclumab

Age Groups: adult | senior
Covered Countries FRA | BEL


No variant requirements are available.